Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Animal ; 13(12): 2932-2938, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31155019

RESUMEN

Vitamins play an essential role in broiler nutrition. They are fundamental for normal metabolic and physiological process, and their requirements for poultry are not fixed and can be affected by multiple factors. In contrast, mycotoxins are a challenging issue because they hinder performance and the immune system. Vitamin supplementation above minimum requirements would permit improvement in productive potential, health, bone and meat quality in a situation of mycotoxin challenge. The objective of this study was to determine the influence of optimum vitamin nutrition in diets contaminated with aflatoxin in broilers from 1 to 44 days of age. A total of 1800 Cobb 500 male chicks were randomized to 15 sets of eight treatment groups, each containing 15 birds using a 2 × 2 × 2 factorial design (commercial vitamin levels and high vitamin levels, two levels of aflatoxin - 0 and 0.5 ppm with binder levels of 0 and 10 000 mg/kg). The mash diets were corn and soybean meal based, formulated according to commercial practices. Feed intake, weight gain and feed conversion were analyzed for birds from 1 to 44 days of age. To determine carcass characteristics (carcass yield, breast yield and leg yield) and black bone syndrome, two birds were slaughtered from each group at 45 days. Other analyses included breast tenderness, water loss by dripping and malonaldehyde concentrations. The results demonstrated that broilers that were fed high levels of vitamins showed better weight gain, feed conversion, carcass yield and breast yield than broilers that were fed diets with commercial vitamin levels (P < 0.05); also, broilers that were fed diets containing 0.5 ppm aflatoxin had lower weight gain, carcass yield and breast yield (P < 0.05). The use of 10 000 mg/kg of binder improved (P < 0.05) feed conversion throughout the rearing period. We conclude that aflatoxin negatively affects performance and carcass yield; however, feeding optimum vitamin nutrition improved these performance traits.


Asunto(s)
Aflatoxinas/efectos adversos , Enfermedades Óseas/veterinaria , Pollos , Carne/análisis , Enfermedades de las Aves de Corral/epidemiología , Vitaminas/metabolismo , Aflatoxinas/administración & dosificación , Alimentación Animal/análisis , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Enfermedades Óseas/epidemiología , Enfermedades Óseas/etiología , Brasil/epidemiología , Pollos/crecimiento & desarrollo , Pollos/fisiología , Dieta/veterinaria , Suplementos Dietéticos/análisis , Masculino , Enfermedades de las Aves de Corral/etiología , Distribución Aleatoria , Vitaminas/administración & dosificación
2.
J Steroid Biochem Mol Biol ; 180: 35-40, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29247782

RESUMEN

The objectives of this study were to: 1) Determine the impact of varying baseline serum 25OHD on increase in vitamin D concentrations after daily supplementation with vitamin D and calcium (1000 IU + 500 mg respectively) for six months in school-children from a semi-rural setting 2) Test the efficacy of daily vitamin D-calcium supplementation on improvement in serum vitamin D concentrations to ≥75 nmol/L. Data collected from 106 subjects (58 boys, 48 girls), aged 6-12 years, included anthropometric measures like height and weight, body composition analysis, three one-day dietary recalls and sunlight exposure (by questionnaire). Blood was collected at baseline and endline and estimated for serum vitamin D by ELISA technique using standard kits. Classification of Vitamin D status was performed according to the 2011 Endocrine Society Practice Guidelines: vitamin D deficiency - <50 nmol/L; insufficiency - 50.0-74.9 nmol/L; sufficiency - ≥75 nmol/L. Statistical analysis was performed using SPSS software. Mean baseline serum vitamin D concentration was 59.7 ±â€¯11.2 nmol/L; this rose to 79.8 ±â€¯23.3 nmol/L with no significant differences between genders at the two time-points. Inverse relationship was obtained between baseline serum 25(OH)D concentrations and change in serum concentrations after supplementation, implying that with increasing baseline serum concentrations of 25(OH)D, increase in vitamin D levels post supplementation were significantly lower (r = - 0.96, p < 0.0001). Greatest benefit of change in serum vitamin D concentrations after supplementation was experienced by children with basal concentrations of <45 nmol/L. Daily vitamin D supplementation was effective in improving serum 25(OH)D to ≥75 nmol/L in 44% of children. Significantly higher percentage of children who were deficient at baseline (64%) were able to attain serum concentrations of ≥75 nmol/L as compared to children who were vitamin D insufficient (43%) (p < 0.001). Thus, daily supplementation with 1000 IU of vitamin D along with 500 mg of calcium helped in improving serum vitamin D concentrations to ≥75 nmol/L. Children who were vitamin D deficient particularly experienced these benefits.


Asunto(s)
Biomarcadores/sangre , Enfermedades Óseas/sangre , Deficiencia de Vitamina D/sangre , Vitamina D/análogos & derivados , Vitamina D/administración & dosificación , Enfermedades Óseas/tratamiento farmacológico , Enfermedades Óseas/epidemiología , Niño , Método Doble Ciego , Femenino , Humanos , India/epidemiología , Masculino , Población Rural , Instituciones Académicas , Vitamina D/sangre , Deficiencia de Vitamina D/tratamiento farmacológico , Deficiencia de Vitamina D/epidemiología , Vitaminas/administración & dosificación
3.
Semin Pediatr Neurol ; 24(4): 301-309, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-29249510

RESUMEN

Antiseizure medications and dietary therapies have associated effects on the endocrine system. We provided an overview of the relationship between epilepsy treatment and bone health in children with epilepsy. Additionally, we discussed the effects of epilepsy treatment on other endocrine systems including thyroid function, growth, reproduction, and weight. The effect of epilepsy on bone health is multifactorial; there are direct and indirect effects of medication and dietary treatments as well as a decrease in physical activity, decreased sunlight exposure, decreased vitamin D levels, and additional comorbidities. Some medications have a greater effect on vitamin D and bone health than others, however all antiseizure medical treatments are associated with lower vitamin D levels in pediatric patients. We have provided practical suggestions for vitamin D surveillance in children with epilepsy as well as replacement strategies. Children with epilepsy have an increased likelihood of additional endocrine disorders including subclinical hypothyroidism, decreased growth, weight abnormalities, reproductive and sexual dysfunction. To a great extent, this is medication specific. Though more studies are needed to elucidate optimal treatment and monitoring of bone health and other endocrinopathies in children with epilepsy, it is critical that caregivers pay close attention to these issues to provide optimal comprehensive care to their patients.


Asunto(s)
Enfermedades Óseas/complicaciones , Enfermedades Óseas/fisiopatología , Enfermedades del Sistema Endocrino/complicaciones , Enfermedades del Sistema Endocrino/fisiopatología , Epilepsia/complicaciones , Epilepsia/fisiopatología , Enfermedades Óseas/epidemiología , Huesos/efectos de los fármacos , Huesos/fisiopatología , Niño , Comorbilidad , Enfermedades del Sistema Endocrino/epidemiología , Epilepsia/tratamiento farmacológico , Epilepsia/epidemiología , Humanos
4.
J Clin Endocrinol Metab ; 102(7): 2321-2328, 2017 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-28379394

RESUMEN

Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present. Methods: Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants. Serum C-terminal telopeptide of type 1 collagen, procollagen type 1 N-terminal propeptide (P1NP), aBMD, and distal radius microstructure and MMD were measured in a second subset of 150 participants. Results: A breakpoint for calcium, PTH, and alkaline phosphatase was identified at a threshold 25(OH)D level <30 nmol/L. There was no plateau beyond 75 nmol/L. In the subgroup with measurements of bone morphology, no associations were detectable between serum 25(OH)D concentration, aBMD, trabecular density, cortical porosity, or MMD. Among 1439 participants with serum 25(OH)D <30 nmol/L, 6.1% had low serum calcium, 3.4% had low serum phosphate, 6.1% had high alkaline phosphatase, and 34.2% had elevated PTH. Most participants did not have any abnormalities. Conclusion: At a 25(OH)D threshold of ≤30 nmol/L, abnormalities in biochemical features support the notion of a "deficiency" state predisposing to bone disease. However, no deleterious effects were found in participants within an insufficiency threshold of a 25(OH)D level of 30 to 75 nmol/L, which challenges the rationale justifying vitamin D supplementation in these individuals.


Asunto(s)
Enfermedades Óseas/etiología , Deficiencia de Vitamina D/complicaciones , Vitamina D/análogos & derivados , Adulto , Anciano , Fosfatasa Alcalina/sangre , Densidad Ósea/fisiología , Enfermedades Óseas/sangre , Enfermedades Óseas/epidemiología , Enfermedades Óseas/fisiopatología , Remodelación Ósea/fisiología , Calcio/sangre , Estudios de Cohortes , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Fosfatos/sangre , Victoria/epidemiología , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/epidemiología , Deficiencia de Vitamina D/fisiopatología
5.
Breast Cancer Res Treat ; 161(3): 501-513, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27915435

RESUMEN

PURPOSE: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. METHODS: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients' demographic, lifestyle, clinical tumor characteristics, as well as bone health history. RESULTS: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. CONCLUSIONS: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.


Asunto(s)
Enfermedades Óseas/complicaciones , Enfermedades Óseas/metabolismo , Remodelación Ósea , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores , Biomarcadores de Tumor , Densidad Ósea , Enfermedades Óseas/epidemiología , Enfermedades Óseas/patología , Neoplasias Óseas/metabolismo , Neoplasias Óseas/secundario , Neoplasias de la Mama/diagnóstico , Ejercicio Físico , Femenino , Fracturas Óseas/epidemiología , Fracturas Óseas/etiología , Fracturas Óseas/metabolismo , Humanos , Estilo de Vida , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Osteoporosis/epidemiología , Osteoporosis/etiología , Osteoporosis/metabolismo , Posmenopausia , Premenopausia , Factores de Riesgo
6.
Nutr Clin Pract ; 32(2): 258-265, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27589260

RESUMEN

BACKGROUND: Previous studies have noticed the high incidence of suboptimal vitamin D (VtD) status and bone loss in short bowel syndrome (SBS) with parenteral nutrition (PN) dependence. However, limited data have focused on adult SBS without PN dependence. Therefore, our objective was to investigate the incidence and risk factors of suboptimal VtD status and bone loss in adult SBS even after weaning off PN. MATERIALS AND METHODS: We performed a prospective study of 60 adult patients with SBS. Serum 25-hydroxyvitamin D (25-OHD) was measured by radioimmunoassay. Bone mineral density (BMD) was measured using dual-energy x-ray absorptiometry (DEXA). Medical records and various laboratory parameters were collected in all participants. RESULTS: Suboptimal VtD status was identified in all individuals, including 3 (5.0%) with VtD insufficiency and 57 (95.0%) with VtD deficiency. Residual small bowel length (B, 0.072, P = .001) and duration of SBS (B, -0.066, P = .020) were both significantly correlated with suboptimal VtD levels. Overall, only 2 patients presented a normal BMD; osteopenia and osteoporosis were noted in 41 (68.3%) and 17 (28.3%) individuals, respectively. Low 25-OHD concentration was associated with a decreased BMD (B, 0.065, P = .029). There were no other demographic characteristics or clinical examinations associated with suboptimal VtD levels and bone loss. CONCLUSION: Suboptimal VtD status and bone loss were common in adult SBS even after weaning off PN. Despite routine oral VtD supplementation, most patients did not achieve satisfactory status. This emphasizes the critical importance of routine surveillance of 25-OHD and BMD, as well as consideration of alternative methods of supplementation after weaning off PN.


Asunto(s)
Enfermedades Óseas/sangre , Enfermedades Óseas/epidemiología , Síndrome del Intestino Corto/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/epidemiología , Vitamina D/sangre , Absorciometría de Fotón , Adulto , Densidad Ósea , Enfermedades Óseas/etiología , Suplementos Dietéticos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estado Nutricional , Nutrición Parenteral/efectos adversos , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Síndrome del Intestino Corto/terapia , Vitamina D/administración & dosificación , Deficiencia de Vitamina D/etiología , Adulto Joven
7.
Ann N Y Acad Sci ; 1368(1): 82-94, 2016 03.
Artículo en Inglés | MEDLINE | ID: mdl-27186941

RESUMEN

Patients with non-transfusion-dependent thalassemia (NTDT) experience a wide array of clinical complications despite their independence from frequent, regular red blood cell (RBC) transfusions. According to the current understanding of NTDT, these clinical complications stem from the interaction of multiple pathophysiological factors: ineffective erythropoiesis, iron overload, and hypercoagulability. The state of chronic anemia and hypoxia-resulting from ineffective erythropoiesis and hemolysis-leads to the expansion of the erythroid marrow and extramedullary hematopoiesis. The chronic ineffective erythropoiesis also triggers increased intestinal iron absorption and deposition in the liver and endocrine glands despite the lack of transfusional iron load. Patients with NTDT also have a higher incidence of thromboembolic disease, pulmonary hypertension, and silent cerebral ischemia. The treatment of NTDT relies on occasional or more frequent blood transfusions for certain indications (severe infection, pregnancy, and surgery), iron chelation therapy, splenectomy, and hydroxyurea. Splenectomy is no longer routinely performed in all patients with NTDT in light of its association with increased risk of NTDT-related complications. This review focuses on the clinical morbidities associated with NTDT, summarizes the mainstays of treatment, and sheds light on future therapeutic directions in the field.


Asunto(s)
Transfusión Sanguínea , Talasemia/epidemiología , Talasemia/terapia , Enfermedades Óseas/epidemiología , Enfermedades Óseas/metabolismo , Enfermedades Óseas/terapia , Eritropoyesis/efectos de los fármacos , Eritropoyesis/fisiología , Humanos , Absorción Intestinal/efectos de los fármacos , Absorción Intestinal/fisiología , Quelantes del Hierro/farmacología , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/epidemiología , Sobrecarga de Hierro/metabolismo , Sobrecarga de Hierro/terapia , Morbilidad , Talasemia/metabolismo , Trombosis/epidemiología , Trombosis/metabolismo , Trombosis/terapia
8.
J Epidemiol ; 26(2): 57-63, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26499132

RESUMEN

BACKGROUND: The prevalence of brick tea-type fluorosis is high in Tibet because of the habit of drinking brick tea in this region. Brick tea-type fluorosis has become an urgent public health problem in China. METHODS: A cross-sectional survey was conducted to investigate prevalence of brick tea-type fluorosis in all districts of Tibet using a stratified cluster sampling method. Dental fluorosis in children aged 8-12 years and clinical skeletal fluorosis in adults were diagnosed according to the national criteria. A total of 423 children and 1320 adults participated in the study. Samples of drinking water, brick tea, brick tea infusion (or buttered tea), and urine were collected and measured for fluoride concentrations by the fluoride ion selective electrode method. RESULTS: The fluoride level in all but one of the brick tea samples was above the national standard. The average daily fluoride intake from drinking brick tea in all seven districts in Tibet was much higher than the national standard. The prevalence of dental fluorosis was 33.57%, and the prevalence of clinical skeletal fluorosis was 46.06%. The average daily fluoride intake from drinking brick tea (r = 0.292, P < 0.05), urine fluoride concentrations in children (r = 0.134, P < 0.05), urine fluoride concentrations in adults (r = 0.162, P < 0.05), and altitude (r = 0.276, P < 0.05) were positively correlated with the prevalence of brick tea-type fluorosis. Herdsmen had the highest fluoride exposure and the most severe skeletal fluorosis. CONCLUSIONS: Brick tea-type fluorosis in Tibet is more serious than in other parts of China. The altitude and occupational factors are important risk factors for brick tea-type fluorosis.


Asunto(s)
Enfermedades Óseas/epidemiología , Exposición a Riesgos Ambientales/efectos adversos , Fluoruros/efectos adversos , Fluorosis Dental/epidemiología , Té/efectos adversos , Adulto , Altitud , Enfermedades Óseas/inducido químicamente , Niño , Estudios Transversales , Exposición a Riesgos Ambientales/estadística & datos numéricos , Fluoruros/administración & dosificación , Fluorosis Dental/etiología , Humanos , Ocupaciones/estadística & datos numéricos , Prevalencia , Factores de Riesgo , Índice de Severidad de la Enfermedad , Té/química , Tibet/epidemiología
9.
Clin Calcium ; 25(11): 1681-8, 2015 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-26503874

RESUMEN

Gastrectomy is undergone mainly in patients with gastric cancer. Bone diseases(osteoporosis and osteomalacia)caused by gastractomy are associated with weight loss, calcium and vitamin D inadequancy, and malnutrition. Most patients after gastrectomy have multile risk factors of bone diseases and subsequently are at a higher risk for fractures. In particular, sex hormone deficiency and aging enhance the risk for fractures. The management of bone diseases caused by gastraectomy include adequet intake of calcium, vitamin D and protein, sunlight exposure, and regular weight-bearing exercise, as well as non-smoking and avoiding excess alcohol drinking. The patients at a high risk for fractures shoud be treated with bisphosphonates.


Asunto(s)
Enfermedades Óseas/prevención & control , Fracturas Óseas/prevención & control , Gastrectomía/efectos adversos , Densidad Ósea , Enfermedades Óseas/complicaciones , Enfermedades Óseas/epidemiología , Suplementos Dietéticos , Terapia por Ejercicio , Humanos
10.
Eur. J. Ost. Clin. Rel. Res ; 10(2): 37-46, mayo-ago. 2015. tab, ilus
Artículo en Español | IBECS | ID: ibc-141063

RESUMEN

Introducción: El estreñimiento funcional es la patología más frecuente en Gastroenterología. Recientes estudios aseveran una presencia del 78% de dolores referidos al aparato locomotor de origen visceral. Objetivos: Evaluar la Maniobra Hemodinámica abdominal modificada (MHAM) en pacientes estreñidos a través del Umbral de dolor a la presión (UDP) en los niveles dorsales T10,T11 y T12, inclinometría para la flexión lumbar, el test de extensibilidad Sit and Reach y la valoración postural del paciente con el programa SAPO. Material y Métodos: Ensayo clínico aleatorizado controlado, a doble ciego en 20 pacientes (n=20); Grupo Control (GC: n=10) y Grupo Experimental (GE: n=10). Resultados: Algometría T11: en el GE la diferencia media fue de 1,05 kg (IC95%=0,501 a 1,603; p=0,001; d Cohen= 0,84). Algometría T12: en el GE la diferencia fue 1,23 kg (IC95%=0,499 a 1,969; p=0,002 significativa; d Cohen=0,89). Inclinometría T12: en el GE se produjo un incremento medio de 10,4º (IC 95%=7,59 a 13,21º; p<0,001; d Cohen=0,94).Test Sit and Reach: en el GE el aumento medio fue de 3,47cm (IC95%= 2,35 a 4,58 cm; p<0,001; d Cohen=0,77). Conclusiones: La aplicación de la Maniobra Hemodinámica Abdominal Modificada en pacientes con estreñimiento funcional genera cambios inmediatos aumentando la tolerancia al dolor en las vértebras T11 y T12, aumentando la flexión lumbar y mejorando la extensibilidad de los miembros inferiores (AU)


No dispoible


Asunto(s)
Estreñimiento/complicaciones , Estreñimiento/diagnóstico , Estreñimiento/patología , Hemodinámica/fisiología , Enfermedades Óseas/complicaciones , Enfermedades Óseas/epidemiología , Osteopatía/métodos , Osteopatía , Fotogrametría/métodos , Método Doble Ciego , Medicina Osteopática/métodos , Medicina Osteopática/normas , Medicina Osteopática/tendencias , Osteopatía/instrumentación , Osteopatía/tendencias , Posición Supina , Análisis de Varianza
11.
Biomed Res Int ; 2015: 735615, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26000302

RESUMEN

Hypovitaminosis D is a worldwide disorder, with a high prevalence in the general population of both Western and developing countries. In HIV patients, several studies have linked vitamin D status with bone disease, neurocognitive impairment, depression, cardiovascular disease, high blood pressure, metabolic syndrome, type 2 diabetes mellitus, infections, autoimmune diseases like type 1 diabetes mellitus, and cancer. In this review, we focus on the most recent epidemiological and experimental data dealing with the relationship between vitamin D deficiency and HIV infection. We analysed the extent of the problem, pathogenic mechanisms, clinical implications, and potential benefits of vitamin D supplementation in HIV-infected subjects.


Asunto(s)
Enfermedades Óseas , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/epidemiología , Terapia Antirretroviral Altamente Activa , Enfermedades Óseas/complicaciones , Enfermedades Óseas/epidemiología , Infecciones por VIH/tratamiento farmacológico , Humanos , Prevalencia , Factores de Riesgo
12.
J Antimicrob Chemother ; 70(4): 1150-4, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25525197

RESUMEN

OBJECTIVES: Nucleotide analogues may promote renal and bone toxicity. The aim of the present study was to evaluate markers of osteorenal toxicity in patients affected by hepatitis B virus-related chronic hepatitis treated with lamivudine plus adefovir who were switched to tenofovir. PATIENTS AND METHODS: We evaluated 60 consecutive patients at the time of the switch of treatment and after 1, 3, 6, 9 and 12 months. The mean baseline estimated glomerular filtration rate (eGFR) was 89.3 ± 19.0 mL/min/1.73 m(2). RESULTS: During the study period we observed a reduction in mean eGFR up to 6 months after switching to tenofovir, and this remained stable for the last two timepoints. At the end of study, the mean eGFR was 82.6 ± 21.5 mL/min/1.73 m(2), a reduction of 7.5%. The mean baseline proteinuria was 202.6 ± 237.6 mg/24 h. Microhaematuria was observed in 22.6% of patients and hypophosphataemia in 18.6%. After 1 month of tenofovir, we observed a worsening of serum phosphate and parathyroid hormone levels, haemoglobinuria and 24 h proteinuria. After 3 and 12 months of tenofovir, these data tended to recover to baseline levels. A total of 92.6% of patients at baseline had hypovitaminosis D. After supplementation with cholecalciferol, this percentage decreased significantly. We observed a reduced bone mineral density (BMD) in 52.7% of patients at baseline; this increased to 77.8% after 6 months of tenofovir, but at the last timepoint the percentage of patients with a reduced BMD had fallen to a level above the baseline. CONCLUSIONS: In conclusion, patients exposed to lamivudine plus adefovir showed relevant osteorenal damage. The switch to tenofovir provoked a slight reduction in eGFR that stabilized after 6 months. The reduced BMD at baseline did not worsen under tenofovir treatment.


Asunto(s)
Antivirales/efectos adversos , Enfermedades Óseas/inducido químicamente , Enfermedades Óseas/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Hepatitis B Crónica/tratamiento farmacológico , Enfermedades Renales/inducido químicamente , Enfermedades Renales/epidemiología , Adenina/efectos adversos , Adenina/análogos & derivados , Adenina/uso terapéutico , Adulto , Anciano , Antivirales/uso terapéutico , Enfermedades Óseas/patología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Tasa de Filtración Glomerular , Hematuria/inducido químicamente , Hematuria/epidemiología , Humanos , Hipofosfatemia/inducido químicamente , Hipofosfatemia/epidemiología , Enfermedades Renales/patología , Lamivudine/efectos adversos , Lamivudine/uso terapéutico , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Organofosfonatos/efectos adversos , Organofosfonatos/uso terapéutico , Proteinuria/inducido químicamente , Proteinuria/epidemiología , Deficiencia de Vitamina D/inducido químicamente , Deficiencia de Vitamina D/epidemiología
13.
Curr Opin Endocrinol Diabetes Obes ; 22(1): 35-40, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25517023

RESUMEN

PURPOSE OF REVIEW: To update the reader's knowledge about the factors that influence bone mineral accrual and to review the advances in the assessment of bone health and treatment of bone disorders. RECENT FINDINGS: Maternal vitamin D status influences neonatal calcium levels, bone mineral density (BMD) and bone size. In turn, BMD z-score tends to track in childhood. These factors highlight the importance of bone health as early as fetal life. Dual-energy x-ray absorptiometry is the mainstay of clinical bone health assessment in this population because of the availability of appropriate reference data. Recently, more information has become available about the assessment and treatment of bone disease in chronically ill pediatric patients. SUMMARY: Bone health must become a health focus starting prenatally in order to maximize peak bone mass and to prevent osteoporosis-related bone disease in adulthood. Vitamin D, calcium and weight-bearing activity are the factors of key importance throughout childhood in achieving optimal bone health as BMD z-score tracks through childhood and into adulthood. Recent updates of the International Society for Clinical Densitometry focus on the appropriate use of dual-energy x-ray absorptiometry in children of all ages, including children with chronic disease, and on the treatment of pediatric bone disease.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Enfermedades Óseas/epidemiología , Huesos/metabolismo , Calcio de la Dieta/uso terapéutico , Vitamina D/uso terapéutico , Absorciometría de Fotón , Densidad Ósea , Huesos/patología , Niño , Fenómenos Fisiológicos Nutricionales Infantiles , Preescolar , Suplementos Dietéticos , Femenino , Humanos , Fenómenos Fisiologicos Nutricionales Maternos
14.
Lancet Diabetes Endocrinol ; 2(4): 307-320, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24703049

RESUMEN

BACKGROUND: Vitamin D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of vitamin D on disorders are needed. METHODS: We did a trial sequential meta-analysis of existing randomised controlled trials of vitamin D supplements, with or without calcium, to investigate the possible effect of future trials on current knowledge. We estimated the effects of vitamin D supplementation on myocardial infarction or ischaemic heart disease, stroke or cerebrovascular disease, cancer, total fracture, hip fracture, and mortality in trial sequential analyses using a risk reduction threshold of 5% for mortality and 15% for other endpoints. FINDINGS: The effect estimate for vitamin D supplementation with or without calcium for myocardial infarction or ischaemic heart disease (nine trials, 48 647 patients), stroke or cerebrovascular disease (eight trials 46 431 patients), cancer (seven trials, 48 167 patients), and total fracture (22 trials, 76 497 patients) lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk of any of these endpoints by 15% or more. Vitamin D supplementation alone did not reduce hip fracture by 15% or more (12 trials, 27 834 patients). Vitamin D co-administered with calcium reduced hip fracture in institutionalised individuals (two trials, 3853 patients) but did not alter the relative risk of hip fracture by 15% or more in community-dwelling individuals (seven trials, 46 237 patients). There is uncertainty as to whether vitamin D with or without calcium reduces the risk of death (38 trials, 81 173). INTERPRETATION: Our findings suggest that vitamin D supplementation with or without calcium does not reduce skeletal or non-skeletal outcomes in unselected community-dwelling individuals by more than 15%. Future trials with similar designs are unlikely to alter these conclusions. FUNDING: Health Research Council of New Zealand.


Asunto(s)
Enfermedades Óseas/prevención & control , Suplementos Dietéticos , Neoplasias/prevención & control , Enfermedades Vasculares/prevención & control , Vitamina D/uso terapéutico , Vitaminas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Óseas/epidemiología , Calcio de la Dieta/uso terapéutico , Determinación de Punto Final , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Enfermedades Vasculares/epidemiología
16.
Eur Rev Med Pharmacol Sci ; 17(9): 1218-32, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23690192

RESUMEN

Hypovitaminosis D is a very common disorder, regarding both Western and developing countries. A growing amount of data over the last years have shown vitamin D deficiency to be high prevalent among HIV-positive subjects. In addition to "classic" risk factors, such as female sex, low dietary intake, dark skin pigmentation and low sun exposure, HIV-related factors, including immune activation and antiretroviral adverse effects, may affect vitamin D status. Even if both protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been associated with low vitamin D levels, available evidences have failed to univocally associate hypovitaminosis D with specific antiretroviral class effects. Low vitamin D is known to have a negative impact not only on bone health, but also on neurocognitive, metabolic, cardiovascular and immune functions. Similarly to the general population, several studies conducted on HIV-infected subjects have associated hypovitaminosis D with a greater risk of developing osteopenia/osteoporosis and fragility fractures. Analogously, vitamin D deficiency has been described as an independent risk factor for cardiovascular disease and metabolic disorders, such as insulin resistance and type 2 diabetes mellitus. Last EACS guidelines suggest to screen for hypovitaminosis D every HIV-positive subject having a history of bone disease, chronic kidney disease or other known risk factors for vitamin D deficiency. Vitamin D repletion is recommended when 25-hydroxyvitamin D levels are below 10 ng/ml. Furthermore, it may be indicated in presence of 25OHD values between 10 and 30 ng/ml, if associated with osteoporosis, osteomalacia or increased parathyroid hormone levels. The optimal repletion and maintenance dosing regimens remain to be established, as well as the impact of vitamin D supplementation in preventing comorbidities.


Asunto(s)
Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Deficiencia de Vitamina D/epidemiología , Deficiencia de Vitamina D/etiología , Terapia Antirretroviral Altamente Activa/efectos adversos , Enfermedades Óseas/epidemiología , Enfermedades Óseas/etiología , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/epidemiología , Humanos , Factores de Riesgo , Vitamina D/sangre , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/diagnóstico , Deficiencia de Vitamina D/terapia , Vitaminas/uso terapéutico
17.
Transplantation ; 95(12): 1479-84, 2013 Jun 27.
Artículo en Inglés | MEDLINE | ID: mdl-23572129

RESUMEN

BACKGROUND: Renal transplant patients have been shown to have a higher risk of bone disease than the general population. The aim of this study was to examine vitamin D status, a modifiable risk factor in bone disease, in the renal transplant population in a northern climate. METHODS: This retrospective observational study included 331 subjects and analyzed demographic, biochemical, and medication information for associations with vitamin D. RESULTS: Of the study population, 45.3% were vitamin D deficient. The percentage of deficient subjects increases to 76.5% if those receiving supplementation are excluded. The mean daily dose of vitamin D was 1275 IU for sufficient patients. For every 1000 IU of vitamin D daily, the risk of deficiency is decreased by 40.3%. Time from transplantation had a significant positive association (P<0.001) in which every year out of transplantation decreased the risk of deficiency by 9.1%. Body mass index had a significant negative association (P=0.012) with vitamin D in which the risk of deficiency increased by 6% for each kilogram per meter squared. Ethnicity was found to be statistically significant on univariate analysis (P=0.034), with white patients having 9.1% decreased risk of deficiency. CONCLUSION: Despite a high rate of supplementation of vitamin D, close to half of the renal transplant population was still deficient. Those who were receiving over 1000 IU daily were more likely to be vitamin D sufficient. Early supplementation after transplantation along with higher doses for non-white patients or patients with a high body mass index may be warranted for normalization of vitamin D status.


Asunto(s)
Enfermedades Óseas/epidemiología , Trasplante de Riñón/efectos adversos , Insuficiencia Renal/complicaciones , Insuficiencia Renal/epidemiología , Deficiencia de Vitamina D/epidemiología , Adulto , Índice de Masa Corporal , Enfermedades Óseas/etiología , Clima , Suplementos Dietéticos , Femenino , Geografía , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia Renal/diagnóstico , Estudios Retrospectivos , Factores de Riesgo , Luz Solar , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/diagnóstico
19.
J Pediatr Endocrinol Metab ; 26(5-6): 469-75, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23423528

RESUMEN

AIM: To evaluate the clinical and biochemical findings of the children and adolescents with vitamin D deficiency and insufficiency in order to determine the clinical and biochemical presentation differences between age groups. METHODS: This retrospective study included a review of medical reports of 543 patients (aged between 1-17 years) who were referred to our hospital between October 2011 and May 2012 with symptoms related to vitamin D deficiency or insufficiency. The patients were divided into four groups by age: 1-3 years (Group 1), 4-6 years (Group 2), 7-11 years (Group 3) and 12-17 years (Group 4). Patients diagnosed with vitamin D deficiency or insufficiency were evaluated as to their clinical and biochemical findings. RESULTS: Gender distribution were not statistically different between the four groups. The mean ages of Groups 1-4 were 1.9±0.7, 5.1±0.9, 8.9±1.3, 13.1±1.1, respectively. Major complaints on admission were muscle weakness (91%), low weight gain (failure to thrive) (89%), head deformity (frontal bossing) (35.6%), bone deformity (enlargement of wrist and ankles) (29.7%) for Group 1. Muscle weakness (76%) and low weight gain (failure to thrive) (68%) for Group 2. Leg and chest pain were the major symptoms in Group 3 (57% and 28%, respectively) and in Group 4 (26% and 55%, respectively) as well as high rates of obesity (31% and 63%). The biochemical findings of vitamin D deficiency mostly appeared in the first group who developed vitamin D deficiency due to the lack of vitamin D supplementation. However, in older children, the majority of the patients had low 25 hydroxyvitamin D (25 OHD) values without evidence of biochemical findings of osteomalacia. CONCLUSION: Depending on the degree of deficiency and insufficiency, and the age of the patients, the clinical and biochemical findings varied widely. Children under the age of 3 who either never received vitamin D supplementation or who had been receiving supplementation that was stopped too early were at a greater risk for developing clinically and biochemically proved vitamin D deficiency. In older children, low vitamin D levels mostly resulted in subtle complaints without abnormal biochemical findings.


Asunto(s)
Insuficiencia de Crecimiento/diagnóstico , Insuficiencia de Crecimiento/metabolismo , Debilidad Muscular/diagnóstico , Debilidad Muscular/metabolismo , Deficiencia de Vitamina D/diagnóstico , Deficiencia de Vitamina D/metabolismo , Adolescente , Enfermedades Óseas/diagnóstico , Enfermedades Óseas/epidemiología , Enfermedades Óseas/metabolismo , Niño , Preescolar , Facies , Insuficiencia de Crecimiento/epidemiología , Femenino , Homeostasis/fisiología , Humanos , Lactante , Resistencia a la Insulina/fisiología , Masculino , Debilidad Muscular/epidemiología , Factores de Riesgo , Deficiencia de Vitamina D/epidemiología
20.
Trop Med Int Health ; 18(2): 222-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23198699

RESUMEN

INTRODUCTION: Fluorosis is endemic throughout the East African Rift valley, including parts of Tanzania. The aim of the study was to identify all cases of deforming juvenile skeletal fluorosis (JSF) in a northern Tanzanian village and to document the extent of dental fluorosis (DF). METHODS: Door-to-door prevalence survey of all residents of the village. Residents were assessed for the presence of DF and JSF. Those with JSF and randomly selected controls from the same age range were further assessed for possible JSF risk factors. RESULTS: The village had a population of 1435. DF was endemic within the population, being present in 911 (75.5%; 95% CI, 73.0-77.9) of dentate individuals who were examined (n = 1207). JSF was present in 56 of 1263 people examined, giving a prevalence of 4.4% (95% CI, 3.3-5.6) and was more common in males. Low body mass index, drinking predominantly well water 3 years previously, not being weaned on bananas, the use of fluoride salts in cooking during childhood and drinking more cups of tea per day were independent predictors of JSF. CONCLUSIONS: Juvenile skeletal fluorosis is a common and preventable public health problem. Providing clean, low-fluoride, piped water to affected communities is of obvious health benefit.


Asunto(s)
Enfermedades Óseas/epidemiología , Fluoruros/efectos adversos , Fluorosis Dental/epidemiología , Adolescente , Adulto , Índice de Masa Corporal , Enfermedades Óseas/etiología , Estudios de Casos y Controles , Niño , Preescolar , Agua Potable/efectos adversos , Agua Potable/análisis , Femenino , Fluorosis Dental/etiología , Humanos , Lactante , Masculino , Prevalencia , Factores de Riesgo , Salud Rural , Índice de Severidad de la Enfermedad , Tanzanía/epidemiología , Té/efectos adversos , Abastecimiento de Agua/análisis , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA